Navigation Links
Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008
Date:2/19/2009

luding purchase accounting related items, non-cash impairment charges and revenue from the sale of Bystolic, gross margins would have been approximately 44.6% for calendar year 2008 compared to 48.0% in the prior year, also adjusted to remove similar items.

The decrease in gross margins excluding the items noted above can generally be attributed to the fact that, on average, the newly acquired former Merck Generics business, particularly in countries outside of the United States, contributes margins that are lower than those realized by Mylan's U.S. subsidiaries. The impact of these lower margins was realized for a full twelve months in calendar year 2008 compared to only three months in calendar year 2007.

For calendar year 2008, the company reported income from operations of $297.9 million compared to a loss from operations of $996.1 million in the prior year. In addition to the items which affected gross profit as discussed above, operating income in the current year was impacted by a non-cash goodwill impairment charge of $385.0 million related to Specialty and net charges related to the settlement of certain litigation in the amount of $16.6 million, while the prior year included a charge of $1.42 billion to write off in-process research and development related to the acquisitions of Matrix and the former Merck Generics business. Excluding these items, operating income was $712.7 million in the current year compared to $590.8 million in the prior.

Interest expense for calendar year 2008 totaled $357.0 million compared to $200.4 million for calendar year 2007. The increase is due to the additional debt incurred to finance the acquisition of the former Merck Generics business during the fourth quarter of calendar year 2007.

Other income, net, was $11.3 million for calendar year 2008, compared to $97.1 million in calendar year 2007. Calendar year 2007 included a $85.0 million non-cash mark
'/>"/>

SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Mylan Announces Pricing of Tender Offers for its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015
2. Mylan to Host Investor Day on October 3, 2007
3. Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD
4. Mylan Announces Appointment of Steven G. Zylstra as Vice President of Global Corporate Communication and Public Relations
5. Mylan Announces Tentative FDA Approval for Lamotrigine Tablets
6. Mylan Announces Final FDA Approval for Balsalazide Disodium Capsules
7. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
8. Mylan Announces Final FDA Approval for Ropinirole Hydrochloride Tablets
9. Mylan Launches First Generic Version of Antihypertensive Sular(R) ER in the United States
10. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
11. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... , March 29, 2015  Caris ... study data in small cell cervical cancer ... Caris Molecular Intelligence®, the company,s panomic, comprehensive ... gene mutations which may explain sensitivities and ... that identification of certain biomarkers may guide ...
(Date:3/27/2015)... YORK , 27. März 2015 /PRNewswire/ ... Prize in Biomedical Science für seine bahnbrechende ... Proteine zwischen Zellkompartimenten transportiert werden, sowie für ... Zellen zur Reaktion auf Stress nutzen, der ... Dr. Walter ist Professor für Biochemie an ...
(Date:3/27/2015)... 2015 WuXi PharmaTech (Cayman) Inc. (NYSE: ... and technology platform company serving the global pharmaceutical, ... an Investigational New Drug (IND) application for WuXi ... has been accepted for review by the China ... In September 2012, MedImmune, the global biologics research ...
(Date:3/26/2015)... March 26, 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" ... after dealing with certain matters, including the appointment of ... on March 26, 2015 (the "Meeting") was adjourned, as ... 2015 at 11:00 a.m. ( Toronto ... changed from that previous disclosed. The Meeting will reconvene ...
Breaking Biology Technology:Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 2Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 4Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 3SQI Diagnostics Inc. Announces Adjournment of Meeting 2
... EAST BRUNSWICK, N.J., Oct. 31 Savient,Pharmaceuticals, Inc. (Nasdaq: ... to the U.S. Food and Drug Administration (FDA) seeking ... its request for a,priority review. Savient,s filing includes data ... as well as data from the Open,Label Extension (OLE) ...
... Corporation (Nasdaq: BJGP; "BMP Sunstone" or the "Company") today,announced that ... 1. Oppenheimer Annual Healthcare Conference, held at the ... is currently scheduled to present at 10:40 am ... this presentation will be available via ...
... SHANGHAI, China, Oct. 31 /Xinhua-PRNewswire/ -- Sundia MediTech,Company, ... company (CRO) received this year,s Deloitte Technology,Fast 50 ... of Deloitte,Technology Fast 50 China Program was announced ... Deloitte Technology Fast 50 Program started in 1995 ...
Cached Biology Technology:Savient Submits Biologics License Application (BLA) for pegloticase 2Savient Submits Biologics License Application (BLA) for pegloticase 3Savient Submits Biologics License Application (BLA) for pegloticase 4BMP Sunstone Announces Participation in November Investor Conferences 2Sundia MediTech Ranked #16 in Deloitte Technology Fast 50 China 2
(Date:3/20/2015)... 20, 2015 Research and Markets ... the "India Sensors Market Forecast and Opportunities ... The sensor market is projected to grow at ... Consumer electronics, automotive, industrial and healthcare sectors are ... country. In addition, adoption of MEMS technology in ...
(Date:3/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has ... Strategic Business Report" report to their offering. ... US$ Thousands. The report provides separate comprehensive analytics for the ... , Europe , Asia-Pacific ... Latin America . Annual estimates and forecasts ...
(Date:3/17/2015)... MedNet Solutions , a global ... management systems, is pleased to announce that company ... in Clinical Trials Southeast conference – March 24-25 ... forum for MedNet to showcase iMedNet , ... eClinical technology platform. We strongly encourage ...
Breaking Biology News(10 mins):India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... for Species Exploration at Arizona State University names the Top ... list for 2009 was published to coincide with the 303rd ... It contains only two new plant species, one of which ... Linnean Society . Nepenthes attenboroughii , a ...
... green fluorescent protein known simply as GFP has revolutionized cell ... scientists to visualize proteins inside of cells and track them ... who discovered and developed the protein as a laboratory tool ... GFP as a fluorescent probe has one major drawback ...
... TU Delft and Molecular Imaging Labs (MI Labs) have ... into one piece of equipment. These techniques are particularly ... as microPET and microSPECT. SPECT and PET can be ... traditional microSPECT and microPET. The new device is known ...
Cached Biology News:Rare carnivorous plant on top 10 list of newly discovered species 2MIT chemists design new way to fluorescently label proteins 2TU Delft and MI Labs merge PET and SPECT biomedical imaging techniques and increase resolution 2
8 different frozen tissues are mounted on positively charged glass slides...
... The T2-04 is an ultra-compact pump available ... (T2-04 TH) and ideal for use in portable ... 7 slpm, this pump works well in environments ... weight, and compact size are critical., Offers ...
Curcumin is an extract of turmeric root with antioxidant, anti-tumor promoter, and anti-inflammatory properties. Curcumin inhibits the induction of NOS in macrophages....
Total Proteins from over 50 different human Alzheimer, Diabetic, Liver Cirrhosis, and Lupus diseased tissues are available....
Biology Products: